CTR20262461 Enlonstobart Non-Small Cell Lung Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook

Turn a newly registered trial into a decision-ready landscape. This focused report examines CTR20262461—SYS6010联合PD-(L)-1单抗用于已切除非小细胞肺癌的Ⅲ期临床研究—using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, Drug & Asset MCP for mechanism and development context, and Company & Deal Intelligence MCP for sponsor background. Explore PatSnap MCP Servers to reproduce the workflow inside an AI research process.

MCP evidence snapshot: 20 July 2026; publication date: 20 July 2026. Trial records can change after the snapshot and should be rechecked before operational decisions.

Why CTR20262461 is a hot trial to watch

Non-Small Cell Lung Cancer is increasingly segmented by mechanism, biomarker, treatment setting, geography and endpoint architecture. CTR20262461 is notable because it evaluates Enlonstobart in a Phase 3 design while 基于独立评审委员会（IRC）评估的无病生存期（DFS） serves as the main decision variable. The critical question is whether the protocol can convert its rationale into a clinically interpretable and operationally credible readout.

PatSnap Clinical Trials MCP makes protocol fields machine-readable, while the companion asset and organization servers add development-status, target and sponsor context.

Trial landscape snapshot

Design and endpoint interpretation

The phase label is only the starting point. Allocation is 随机化, masking is 开放, and the intervention model is 平行分组. Planned enrollment of 570 participants across China shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.

• Primary: 基于独立评审委员会（IRC）评估的无病生存期（DFS） (整个研究期间)
• Secondary: 总生存期（OS） (整个研究期间)
• Secondary: 研究者评估的DFS (整个研究期间)
• Secondary: 不良事件（AE）、体格检查、生命体征、实验室检查（包括血常规、血生化、尿常规、凝血功能等）、心电图等；基于EORTC QLQ-C30评估的生活质量指标 (整个研究期间)
• Secondary: SYS6010单次及连续给药后毒素结合的抗体、总抗体及游离毒素（JS-1）的血药浓度；恩朗苏拜单抗单次及多次给药后的血药浓度 (整个研究期间)

Benchmark readouts in the surrounding field

• Randomized Phase II Trial of Individualized Adaptive Radiotherapy Using During-Treatment FDG-PET/CT and Modern Technology in Locally Advanced Non-Small Cell Lung Cancer (NSCLC) (Phase 2): Percentage of Participants Alive Without Local-regional Progression [Local-regional Progression-free (LRPF) Survival] at Two Years (NRG): P-Value = 0.6585; Percentage of Participants Alive Without Local-regional Progression [Local-regional Progression-free (LRPF) Survival] at Two Years (NRG): P-Value = 0.6585
• A Phase II, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Patients With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (Phase 2): Number of Participants With Surgical Delays = 0 Participants ; Number of Participants With Surgical Delays = 4 Participants
• AdvanTIG-205: A Phase 2, Randomized Study of Ociperlimab (BGB-A1217) and Tislelizumab With Chemotherapy in Patients With Previously Untreated Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer (NSCLC) (Phase 2): PFS(Median) = 8.1 Months (95% Confidence Interval, 6.0 - 10.2); PFS(Median): Hazard Ratio (HR) = 0.99(95% CI, 0.74 - 1.33), P-Value = 0.4698

These indexed results are contextual benchmarks, not direct head-to-head evidence. Population, treatment line, endpoint definitions, follow-up and analysis sets may differ. Their value is to clarify the type and magnitude of evidence already visible in the competitive landscape.

Build a living trial monitor: connect to PatSnap MCP Servers and track status changes, endpoint revisions, primary-completion dates and newly indexed results without manually reconciling separate databases.

Asset and sponsor context

Drug & Asset context: Enlonstobart (Approved; PD-1); SYS-6010 (Phase 3; EGFR C797S x EGFR T790M x EGFR-Ex19del)

Company & Deal Intelligence context: CSPC Megalith Biopharmaceutial Co., Ltd. — China — http://www.e-cspc.com

The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can decide whether a positive signal becomes a competitive asset.

White space around this program

• Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
• Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
• Sequencing evidence: comparative data after the most relevant contemporary standard of care.
• Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
• Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.

What to monitor next

Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter probability of success before a headline data release.

Bottom line

CTR20262461 is a focused lens on Non-Small Cell Lung Cancer development. Its value will be determined by whether Enlonstobart can convert the current design into evidence that is clinically meaningful, operationally credible and differentiated from indexed benchmark readouts.

Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.